United States Malignant Melanoma Drug Market Report 2016

November 2016 | 102 pages | ID: U6E7EC546E5EN
QYResearch

Abstracts

Notes:

Sales, means the sales volume of Malignant Melanoma Drug

Revenue, means the sales value of Malignant Melanoma Drug

Revenue, means the salies sales (consumption) of Malignant Melanoma Drug in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

• Bristol-Myers Squibb
• Enzon Pharmaceuticals
• Exelixis
• GlaxoSmithKline
• Merck
• Navidea Biopharmaceuticals
• Novartis
• Ono Pharmaceutical
• Pfizer
• Roche

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

• Immunotherapy
• Targeted therapy
• Others

Split by applications, this report focuses on sales, market share and growth rate of Malignant Melanoma Drug in each application, can be divided into

• Hospital use
• Clinic use
• Application 3

Contents

United States Malignant Melanoma Drug Market Report 2016

1 MALIGNANT MELANOMA DRUG OVERVIEW

1.1 Product Overview and Scope of Malignant Melanoma Drug
1.2 Classification of Malignant Melanoma Drug
  1.2.1 Immunotherapy
  1.2.2 Targeted therapy
  1.2.3 Others
1.3 Application of Malignant Melanoma Drug
  1.3.1 Hospital use
  1.3.2 Clinic use
  1.3.3 Application
1.4 United States Market Size Sales (Value) and Revenue (Volume) of Malignant Melanoma Drug (2011-2021)
  1.4.1 United States Malignant Melanoma Drug Sales and Growth Rate (2011-2021)
  1.4.2 United States Malignant Melanoma Drug Revenue and Growth Rate (2011-2021)

2 UNITED STATES MALIGNANT MELANOMA DRUG COMPETITION BY MANUFACTURERS

2.1 United States Malignant Melanoma Drug Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Malignant Melanoma Drug Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Malignant Melanoma Drug Average Price by Manufactures (2015 and 2016)
2.4 Malignant Melanoma Drug Market Competitive Situation and Trends
  2.4.1 Malignant Melanoma Drug Market Concentration Rate
  2.4.2 Malignant Melanoma Drug Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES MALIGNANT MELANOMA DRUG SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2011-2016)

3.1 United States Malignant Melanoma Drug Sales and Market Share by Type (2011-2016)
3.2 United States Malignant Melanoma Drug Revenue and Market Share by Type (2011-2016)
3.3 United States Malignant Melanoma Drug Price by Type (2011-2016)
3.4 United States Malignant Melanoma Drug Sales Growth Rate by Type (2011-2016)

4 UNITED STATES MALIGNANT MELANOMA DRUG SALES (VOLUME) BY APPLICATION (2011-2016)

4.1 United States Malignant Melanoma Drug Sales and Market Share by Application (2011-2016)
4.2 United States Malignant Melanoma Drug Sales Growth Rate by Application (2011-2016)
4.3 Market Drivers and Opportunities

5 UNITED STATES MALIGNANT MELANOMA DRUG MANUFACTURERS PROFILES/ANALYSIS

5.1 Bristol-Myers Squibb
  5.1.1 Company Basic Information, Manufacturing Base and Competitors
  5.1.2 Malignant Melanoma Drug Product Type, Application and Specification
    5.1.2.1 Type I
    5.1.2.2 Type II
  5.1.3 Bristol-Myers Squibb Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
  5.1.4 Main Business/Business Overview
5.2 Enzon Pharmaceuticals
  5.2.2 Malignant Melanoma Drug Product Type, Application and Specification
    5.2.2.1 Type I
    5.2.2.2 Type II
  5.2.3 Enzon Pharmaceuticals Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
  5.2.4 Main Business/Business Overview
5.3 Exelixis
  5.3.2 Malignant Melanoma Drug Product Type, Application and Specification
    5.3.2.1 Type I
    5.3.2.2 Type II
  5.3.3 Exelixis Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
  5.3.4 Main Business/Business Overview
5.4 GlaxoSmithKline
  5.4.2 Malignant Melanoma Drug Product Type, Application and Specification
    5.4.2.1 Type I
    5.4.2.2 Type II
  5.4.3 GlaxoSmithKline Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
  5.4.4 Main Business/Business Overview
5.5 Merck
  5.5.2 Malignant Melanoma Drug Product Type, Application and Specification
    5.5.2.1 Type I
    5.5.2.2 Type II
  5.5.3 Merck Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
  5.5.4 Main Business/Business Overview
5.6 Navidea Biopharmaceuticals
  5.6.2 Malignant Melanoma Drug Product Type, Application and Specification
    5.6.2.1 Type I
    5.6.2.2 Type II
  5.6.3 Navidea Biopharmaceuticals Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
  5.6.4 Main Business/Business Overview
5.7 Novartis
  5.7.2 Malignant Melanoma Drug Product Type, Application and Specification
    5.7.2.1 Type I
    5.7.2.2 Type II
  5.7.3 Novartis Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
  5.7.4 Main Business/Business Overview
5.8 Ono Pharmaceutical
  5.8.2 Malignant Melanoma Drug Product Type, Application and Specification
    5.8.2.1 Type I
    5.8.2.2 Type II
  5.8.3 Ono Pharmaceutical Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
  5.8.4 Main Business/Business Overview
5.9 Pfizer
  5.9.2 Malignant Melanoma Drug Product Type, Application and Specification
    5.9.2.1 Type I
    5.9.2.2 Type II
  5.9.3 Pfizer Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
  5.9.4 Main Business/Business Overview
5.10 Roche
  5.10.2 Malignant Melanoma Drug Product Type, Application and Specification
    5.10.2.1 Type I
    5.10.2.2 Type II
  5.10.3 Roche Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
  5.10.4 Main Business/Business Overview

6 MALIGNANT MELANOMA DRUG MANUFACTURING COST ANALYSIS

6.1 Malignant Melanoma Drug Key Raw Materials Analysis
  6.1.1 Key Raw Materials
  6.1.2 Price Trend of Key Raw Materials
  6.1.3 Key Suppliers of Raw Materials
  6.1.4 Market Concentration Rate of Raw Materials
6.2 Proportion of Manufacturing Cost Structure
  6.2.1 Raw Materials
  6.2.2 Labor Cost
  6.2.3 Manufacturing Expenses
6.3 Manufacturing Process Analysis of Malignant Melanoma Drug

7 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

7.1 Malignant Melanoma Drug Industrial Chain Analysis
7.2 Upstream Raw Materials Sourcing
7.3 Raw Materials Sources of Malignant Melanoma Drug Major Manufacturers in 2015
7.4 Downstream Buyers

8 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

8.1 Marketing Channel
  8.1.1 Direct Marketing
  8.1.2 Indirect Marketing
  8.1.3 Marketing Channel Development Trend
8.2 Market Positioning
  8.2.1 Pricing Strategy
  8.2.2 Brand Strategy
  8.2.3 Target Client
8.3 Distributors/Traders List

9 MARKET EFFECT FACTORS ANALYSIS

9.1 Technology Progress/Risk
  9.1.1 Substitutes Threat
  9.1.2 Technology Progress in Related Industry
9.2 Consumer Needs/Customer Preference Change
9.3 Economic/Political Environmental Change

10 UNITED STATES MALIGNANT MELANOMA DRUG MARKET FORECAST (2016-2021)

10.1 United States Malignant Melanoma Drug Sales, Revenue Forecast (2016-2021)
10.2 United States Malignant Melanoma Drug Sales Forecast by Type (2016-2021)
10.3 United States Malignant Melanoma Drug Sales Forecast by Application (2016-2021)
10.4 Malignant Melanoma Drug Price Forecast (2016-2021)

11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX

Disclosure Section
Research Methodology
Data Source
Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Malignant Melanoma Drug
Table Classification of Malignant Melanoma Drug
Figure United States Sales Market Share of Malignant Melanoma Drug by Type in 2015
Figure Immunotherapy Picture
Figure Targeted therapy Picture
Figure Others Picture
Table Application of Malignant Melanoma Drug
Figure United States Sales Market Share of Malignant Melanoma Drug by Application in 2015
Figure Hospital use Examples
Figure Clinic use Examples
Figure United States Malignant Melanoma Drug Sales and Growth Rate (2011-2021)
Figure United States Malignant Melanoma Drug Revenue and Growth Rate (2011-2021)
Table United States Malignant Melanoma Drug Sales of Key Manufacturers (2015 and 2016)
Table United States Malignant Melanoma Drug Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Malignant Melanoma Drug Sales Share by Manufacturers
Figure 2016 Malignant Melanoma Drug Sales Share by Manufacturers
Table United States Malignant Melanoma Drug Revenue by Manufacturers (2015 and 2016)
Table United States Malignant Melanoma Drug Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Malignant Melanoma Drug Revenue Share by Manufacturers
Table 2016 United States Malignant Melanoma Drug Revenue Share by Manufacturers
Table United States Market Malignant Melanoma Drug Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Malignant Melanoma Drug Average Price of Key Manufacturers in 2015
Figure Malignant Melanoma Drug Market Share of Top 3 Manufacturers
Figure Malignant Melanoma Drug Market Share of Top 5 Manufacturers
Table United States Malignant Melanoma Drug Sales by Type (2011-2016)
Table United States Malignant Melanoma Drug Sales Share by Type (2011-2016)
Figure United States Malignant Melanoma Drug Sales Market Share by Type in 2015
Table United States Malignant Melanoma Drug Revenue and Market Share by Type (2011-2016)
Table United States Malignant Melanoma Drug Revenue Share by Type (2011-2016)
Figure Revenue Market Share of Malignant Melanoma Drug by Type (2011-2016)
Table United States Malignant Melanoma Drug Price by Type (2011-2016)
Figure United States Malignant Melanoma Drug Sales Growth Rate by Type (2011-2016)
Table United States Malignant Melanoma Drug Sales by Application (2011-2016)
Table United States Malignant Melanoma Drug Sales Market Share by Application (2011-2016)
Figure United States Malignant Melanoma Drug Sales Market Share by Application in 2015
Table United States Malignant Melanoma Drug Sales Growth Rate by Application (2011-2016)
Figure United States Malignant Melanoma Drug Sales Growth Rate by Application (2011-2016)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Bristol-Myers Squibb Malignant Melanoma Drug Sales Market Share (2011-2016)
Table Enzon Pharmaceuticals Basic Information List
Table Enzon Pharmaceuticals Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
Table Enzon Pharmaceuticals Malignant Melanoma Drug Sales Market Share (2011-2016)
Table Exelixis Basic Information List
Table Exelixis Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
Table Exelixis Malignant Melanoma Drug Sales Market Share (2011-2016)
Table GlaxoSmithKline Basic Information List
Table GlaxoSmithKline Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
Table GlaxoSmithKline Malignant Melanoma Drug Sales Market Share (2011-2016)
Table Merck Basic Information List
Table Merck Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
Table Merck Malignant Melanoma Drug Sales Market Share (2011-2016)
Table Navidea Biopharmaceuticals Basic Information List
Table Navidea Biopharmaceuticals Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
Table Navidea Biopharmaceuticals Malignant Melanoma Drug Sales Market Share (2011-2016)
Table Novartis Basic Information List
Table Novartis Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
Table Novartis Malignant Melanoma Drug Sales Market Share (2011-2016)
Table Ono Pharmaceutical Basic Information List
Table Ono Pharmaceutical Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
Table Ono Pharmaceutical Malignant Melanoma Drug Sales Market Share (2011-2016)
Table Pfizer Basic Information List
Table Pfizer Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
Table Pfizer Malignant Melanoma Drug Sales Market Share (2011-2016)
Table Roche Basic Information List
Table Roche Malignant Melanoma Drug Sales, Revenue, Price and Gross Margin (2011-2016)
Table Roche Malignant Melanoma Drug Sales Market Share (2011-2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Malignant Melanoma Drug
Figure Manufacturing Process Analysis of Malignant Melanoma Drug
Figure Malignant Melanoma Drug Industrial Chain Analysis
Table Raw Materials Sources of Malignant Melanoma Drug Major Manufacturers in 2015
Table Major Buyers of Malignant Melanoma Drug
Table Distributors/Traders List
Figure United States Malignant Melanoma Drug Production and Growth Rate Forecast (2016-2021)
Figure United States Malignant Melanoma Drug Revenue and Growth Rate Forecast (2016-2021)
Table United States Malignant Melanoma Drug Production Forecast by Type (2016-2021)
Table United States Malignant Melanoma Drug Consumption Forecast by Application (2016-2021)